Exponent, Inc. — Form 10-Q summary
Reporting period: Quarter and six months ended July 1, 2022, compared with periods ended July 2, 2021. The request metadata says “2021 Q2,” but the filing itself is for the second quarter of 2022.
Business context and financial performance
Exponent provides multidisciplinary engineering and scientific consulting. Its two reportable segments are Engineering and Other Scientific, and Environmental and Health. Unless noted otherwise, amounts below are in millions of dollars.
| Metric | Q2 2022 | Q2 2021 | Six months 2022 | Six months 2021 |
|---|---|---|---|---|
| Revenue | $130.3 | $119.9 | $258.8 | $236.4 |
| Revenue before reimbursements | $118.2 | $112.5 | $236.1 | $222.0 |
| Operating income | $45.3 | $29.4 | $82.0 | $53.4 |
| Net income | $25.8 | $25.4 | $55.4 | $56.2 |
| Diluted EPS | $0.49 | $0.48 | $1.05 | $1.06 |
| Operating cash flow | Not presented by quarter | $23.8 | $45.5 |
Q2 revenue grew 8.7% (5% before reimbursements); six-month revenue grew 9.5% (6.3% before reimbursements). Q2 operating margin was 34.8% of reported revenue, versus 24.5% a year earlier. The company’s non-GAAP EBITDA margin on revenue before reimbursements was 31.4% for Q2 versus 32.3%; for the six-month periods it was 30.3% versus 30.6%.
Material changes and financial position
- Engineering and Other Scientific revenue rose 11.2% in Q2 and 11.5% for the first six months, supported by higher billable hours and billing rates. Environmental and Health revenue fell 2.8% in Q2 but edged up 0.9% for six months; foreign exchange and lower utilization affected results.
- Q2 net income increased 1.4%, while six-month net income declined 1.6%. Q2 diluted EPS was $0.49 versus $0.48; six-month EPS was $1.05 versus $1.06.
- Operating income increased sharply, but results were affected by market-value changes in the deferred compensation plan: compensation expense fell while other income also declined by corresponding amounts. The Q2 other-income line was a loss of $9.8 million, versus income of $5.3 million in the prior-year quarter. These offsetting effects make operating-income growth less representative of underlying performance.
- Cash and cash equivalents were $165.6 million at July 1, down from $297.7 million at year-end 2021. Current assets were $342.5 million and current liabilities $127.5 million. The filing reports no debt balance.
- Six-month operating cash flow fell to $23.8 million from $45.5 million, reflecting working-capital movements, including higher receivables and lower accrued payroll and deferred revenue. Capital expenditures were $5.9 million in cash-flow reporting. Financing used $148.5 million, including $111.8 million in share repurchases and $24.9 million in dividends.
- Stockholders’ equity was $337.5 million, down from $417.1 million at December 31, 2021, primarily reflecting repurchases and dividends. The company repurchased 720,000 shares in Q2 for approximately $63.3 million; $106.6 million remained authorized under its repurchase programs at quarter-end.
Outlook, risks, and unusual items
- Management said cash, cash generated from operations, and cash equivalents should be sufficient for working capital, capital expenditures, commitments, repurchases, dividends, and other liquidity needs for at least the next 12 months. No specific revenue or earnings guidance was provided.
- Management expects compensation costs excluding deferred-compensation market effects, other operating costs, and general and administrative expenses to rise as it hires, invests in infrastructure and business development, and increases office activity and travel.
- Q2 billable hours increased 2%, but utilization declined to 77% from 79%; technical full-time equivalent employees increased 5% to 934. Management cited demand in consumer products, chemicals, automotive, life sciences, utilities, energy storage, litigation, product safety, and recalls.
- One client generated 15% of Q2 revenue and 14% of six-month revenue. Foreign-currency movements, particularly the British pound, may affect results; the company does not hedge foreign-currency exposures. The filing also identifies demand changes, engagement timing, competition, recruiting and retention, COVID-19 effects, and client collectability as risks.
- The company reported no material legal proceedings and no material changes to previously disclosed risk factors. Management concluded disclosure controls were effective and reported no material internal-control changes. A $0.24-per-share dividend was declared July 28, payable September 23, 2022.
Important facts for investors to verify
- Whether revenue growth and utilization trends persist, especially in Engineering and Other Scientific and Environmental and Health.
- How much reported operating-income growth reflects consulting operations versus deferred-compensation market movements and related offsets.
- Whether receivables and operating cash flow improve, and whether cash remains adequate alongside planned repurchases and dividends.
- The effect of major-client concentration, foreign-exchange exposure, and expected increases in compensation and overhead costs.